Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
xylo+dex · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| xylo+dex nasal spray (0.1 mg+5 mg/dose) | EXPERIMENTAL | Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days. |
| Nasic | ACTIVE_COMPARATOR | Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days. |
| Name | Type | Description |
|---|---|---|
| xylo+dex nasal spray (0.1 mg+5 mg/dose) | DRUG | Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days. |
| Nasic | DRUG | Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days. |
Inclusion Criteria * Subjects of 18 years of age or older; * Subjects suffering from nasal congestion with a clinical diagnosis of acute upper respiratory tract infection where symptoms of nasal congestion have persisted for minimum of 3 hours and maximum of 36 hours; * Body mass index (BMI) 18.5 t...
xylo+dex is a nasal spray combination product being developed for the treatment of nasal congestion. It combines xylometazoline and dexpanthenol in a fixed-dose formulation. The program is in Phase 3 development, and the single registered trial in the program has been completed.
xylo+dex is developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The product is a small molecule nasal spray combination of xylometazoline and dexpanthenol, studied for nasal congestion.
xylo+dex is in Phase 3 development. One Phase 3 trial has been completed and no trials are currently active. The completed study was randomized, double blind, and active controlled, enrolling 140 participants with nasal congestion.
xylo+dex has been studied in one clinical trial, NCT03439436, titled a study to compare two formulations of xylometazoline/dexpanthenol nasal spray for the treatment of nasal congestion. The Phase 3 trial is completed, enrolled 140 adults aged 18 and older, and was conducted in Russia.